Matches in Wikidata for { <http://www.wikidata.org/entity/Q92101671> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- Q92101671 description "article scientifique publié en 2019" @default.
- Q92101671 description "artículu científicu espublizáu n'avientu de 2019" @default.
- Q92101671 description "scientific article published on 01 December 2019" @default.
- Q92101671 description "wetenschappelijk artikel" @default.
- Q92101671 description "наукова стаття, опублікована 1 грудня 2019" @default.
- Q92101671 name "Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma" @default.
- Q92101671 name "Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma" @default.
- Q92101671 type Item @default.
- Q92101671 label "Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma" @default.
- Q92101671 label "Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma" @default.
- Q92101671 prefLabel "Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma" @default.
- Q92101671 prefLabel "Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma" @default.
- Q92101671 P1433 Q92101671-F64B6EC5-AAB8-4DF0-AD79-7A21CD117A47 @default.
- Q92101671 P1476 Q92101671-C87DB69A-4250-47EA-B628-6BA78149D5EB @default.
- Q92101671 P2093 Q92101671-4211E53A-7F12-4DC1-A974-F44300137FAD @default.
- Q92101671 P2093 Q92101671-469A3632-254A-4C54-9FCF-2A2D33472F83 @default.
- Q92101671 P2093 Q92101671-51C2173D-3157-4B94-9937-23635048F323 @default.
- Q92101671 P2093 Q92101671-86F02D78-8F14-473F-B02E-D6F6665518E2 @default.
- Q92101671 P2093 Q92101671-92E89720-0B13-4B36-BDB8-C57A4225361E @default.
- Q92101671 P2093 Q92101671-C88313B9-1CC4-403E-B9E0-CC45FBE83D92 @default.
- Q92101671 P304 Q92101671-CE7B7042-A5F0-4C6A-A73A-EDD5BD00E08B @default.
- Q92101671 P31 Q92101671-50325B4A-91CA-44FF-9CF1-AD865273879F @default.
- Q92101671 P356 Q92101671-1D9FCF79-0D59-4676-BFA0-1E068B996260 @default.
- Q92101671 P433 Q92101671-ED8BA8C3-2C4F-4696-A383-73999F11CF15 @default.
- Q92101671 P478 Q92101671-A138A5B9-F7BA-4F6D-8BD9-13C42F6C67BD @default.
- Q92101671 P50 Q92101671-D149C1D8-66BB-43AB-9E81-9018D8503019 @default.
- Q92101671 P577 Q92101671-E0009838-DD27-4B4F-9F83-B58AB6F86C61 @default.
- Q92101671 P698 Q92101671-0F0261E0-0F53-4D5F-9D54-10E73023F866 @default.
- Q92101671 P921 Q92101671-01046BDE-4457-4EB2-B5F8-78B208C2E885 @default.
- Q92101671 P921 Q92101671-296D33D8-72A7-4EDB-B210-7C30CABFCE3F @default.
- Q92101671 P921 Q92101671-6CDFBCD3-6EE2-47F5-94F8-8338E6A07BA8 @default.
- Q92101671 P356 CMR.0000000000000592 @default.
- Q92101671 P698 30829928 @default.
- Q92101671 P1433 Q6811488 @default.
- Q92101671 P1476 "Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma" @default.
- Q92101671 P2093 "Aaron D Bossler" @default.
- Q92101671 P2093 "Michele Freesmeier" @default.
- Q92101671 P2093 "Mohammed Milhem" @default.
- Q92101671 P2093 "Varun Monga" @default.
- Q92101671 P2093 "Weizhou Zhang" @default.
- Q92101671 P2093 "Yousef Zakharia" @default.
- Q92101671 P304 "643-647" @default.
- Q92101671 P31 Q13442814 @default.
- Q92101671 P356 "10.1097/CMR.0000000000000592" @default.
- Q92101671 P433 "6" @default.
- Q92101671 P478 "29" @default.
- Q92101671 P50 Q83863838 @default.
- Q92101671 P577 "2019-12-01T00:00:00Z" @default.
- Q92101671 P698 "30829928" @default.
- Q92101671 P921 Q13896859 @default.
- Q92101671 P921 Q18975855 @default.
- Q92101671 P921 Q425088 @default.